Merck pulls Keytruda for SCLC: On March 1, 2021, pharmaceutical company, Merck announced plans to pull Ketruda for SCLC. Merck’s Keytruda ( pembrolizumab) is the dominant checkpoint inhibitor in the immuno-oncology space, approved for a laundry list of cancer indications. In the third quarter of 2020 alone, Keytruda had sales of $3.7 billion, an increase of […]